Archives of dermatological research · 2025
Therapeutic implications of baricitinib in mouse model of vitiligo.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kaur Harjot, Thakur Kanika, Parsad Davinder, Kumar Ravinder
Аннотация
INTRODUCTION: Vitiligo, an autoimmune disorder marked by skin depigmentation, is closely linked to immune dysregulation, including T cell infiltration and pro-inflammatory cytokines. This study explores the potential of baricitinib, a JAK-STAT inhibitor, in promoting repigmentation in vitiligo lesions by modulating immune responses.
METHODS: Using a mouse model of vitiligo induced by hydroquinone, we assessed the effects of baricitinib treatment on lesion repigmentation, CD8 + T cell infiltration, T cell populations, and serum TNF-α levels. Immunostaining, flow cytometry, and ELISA were used to analyse these parameters.
RESULTS: Baricitinib treatment significantly reduced CD8 + T cell infiltration in the skin, lowered serum TNF-α levels, and decreased both CD4 + and CD8 + T cell populations in the blood. Remarkably, these immune modulations correlated with notable repigmentation of the lesions.
CONCLUSION: Baricitinib effectively reduces inflammation and T cell infiltration, suggesting it as a promising therapeutic for vitiligo. These findings highlight its potential to modulate immune responses and restore skin pigmentation in vitiligo patients.
METHODS: Using a mouse model of vitiligo induced by hydroquinone, we assessed the effects of baricitinib treatment on lesion repigmentation, CD8 + T cell infiltration, T cell populations, and serum TNF-α levels. Immunostaining, flow cytometry, and ELISA were used to analyse these parameters.
RESULTS: Baricitinib treatment significantly reduced CD8 + T cell infiltration in the skin, lowered serum TNF-α levels, and decreased both CD4 + and CD8 + T cell populations in the blood. Remarkably, these immune modulations correlated with notable repigmentation of the lesions.
CONCLUSION: Baricitinib effectively reduces inflammation and T cell infiltration, suggesting it as a promising therapeutic for vitiligo. These findings highlight its potential to modulate immune responses and restore skin pigmentation in vitiligo patients.